Clinical trials: Stage II Breast Carcinoma
Breast Cancer Triple Negative
Neoadjuvant Goserelin for Triple Negative Breast Cancer
This is a phase II randomized trial that will evaluate the effect of adding LHRH analogue, goserelin, to the standard neoadjuvant chemotherapy to patients with triple negative breast cancer.
- Trial name
- NeoGONT (NCT03444025)
- Testing
- Goserelin
- Volunteers
- 180 people
- Sponsor
- Kasr El Aini Hospital
Breast Cancer
Combination Chemotherapy in Treating Women With Stage II or Stage IIIA Breast Cancer That Has Spread to the Lymph Nodes
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known which regimen of chemotherapy is more effective for breast cancer.
- Trial name
- NCT00004125
- Testing
- cyclophosphamide, docetaxel, doxorubicin hydrochloride
- Where
- 48 sites in United States
- Sponsor
- Eastern Cooperative Oncology Group
Breast Cancer
Evaluation of Neoadjuvant Therapy With Trastuzumab, Pertuzumab, Docetaxel, and QL1706 in Early or Locally Advanced HER2+ Breast Cancer
This study is a multicenter, prospective, randomized phase II trial designed to observe and evaluate the efficacy and safety of trastuzumab, pertuzumab, docetaxel combined with QL1706 versus combined with carboplatin as…
- Trial name
- NCT07246317
- Testing
- QL1706 injection, Trastuzumab (or biosimilar), Pertuzumab (or biosimilar)
- Where
- 8 sites in China
- Volunteers
- 188 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Breast Cancer
Gene Therapy Plus Chemotherapy in Treating Patients With Breast Cancer
Phase I trial to study the effectiveness of gene therapy plus chemotherapy in treating patients who have breast cancer. Inserting the p53 gene into a person's cancer cells may improve the body's ability to fight cancer or make…
- Trial name
- NCT00004038
- Testing
- Ad5CMV-p53 gene, chemotherapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer
RATIONALE: Diagnostic procedures that detect tumor cells in the bone marrow may help doctors predict disease recurrence and plan more effective treatment.
- Trial name
- NCT00089323
- Testing
- Bone Marrow Aspiration
- Where
- 53 sites in United States, Canada
- Volunteers
- 1,630 people
- Sponsor
- NSABP Foundation Inc
Breast Cancer
A Study of Whole Brain Radiation Therapy and Capecitabine in Breast Cancer Participants With Newly Diagnosed Brain Metastasis
This open-label, randomized, parallel arm study will evaluate the effect of capecitabine administered concurrently with WBRT and as maintenance therapy in participants with breast cancer and newly diagnosed brain metastases.
- Trial name
- XERAD (NCT00977379)
- Testing
- WBRT, Capecitabine, Standard of Care
- Where
- 16 sites in France
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
HER2-positive Breast Cancer
PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer
DEMETHER is a phase II trial exploring the maintenance of trastuzumab and pertuzumab fixed dose combination (FDC) for subcutaneous administration (SC, PHESGO) following trastuzumab deruxtecan (T-DXd) as induction treatment for…
- Trial name
- DEMETHER (NCT06172127)
- Testing
- Trastuzumab deruxtecan, Phesgo 1,200 MG / 600 MG / 30,000 UNT Per 15 ML Injection, Phesgo 600 MG / 600 MG / 20,000 UNT in 10 mL Injection
- Where
- 36 sites in United States, France and 3 more
- Volunteers
- 165 people
- Sponsor
- MedSIR
Breast Cancer, HER2 Gene Mutation
Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
A Phase II Study of Pyrotinib in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer
- Trial name
- NCT03412383
- Testing
- Pyrotinib
- Where
- China
- Volunteers
- 14 people
- Sponsor
- Peking Union Medical College
Breast Cancer
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as epirubicin, cyclophosphamide, docetaxel, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00288002
- Testing
- trastuzumab, capecitabine, cyclophosphamide
- Where
- Germany
- Volunteers
- 1,500 people
- Sponsor
- GBG Forschungs GmbH
Metastatic Breast Cancer, Locally Advanced Breast Cancer
HOPE: Olaparib, Palbociclib and Fulvestrant in Patients With BRCA Mutation-associated, HR+, HER2-metastatic Breast Cancer
The main purpose of this research study is to learn whether the investigational combination of olaparib, palbociclib, and fulvestrant is safe in patients with estrogen receptor-positive breast cancer and BRCA1 or BRCA2 mutations.
- Conditions
- Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation
- Trial name
- NCT03685331
- Testing
- Palbociclib, Olaparib, Fulvestrant
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Anxiety Disorder, Breast Cancer
Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
RATIONALE: Cranial microcurrent electrical stimulation (CES) is mild electrical current received through electrodes placed on the earlobes. CES may lessen symptoms in women with breast cancer receiving chemotherapy.
- Conditions
- Anxiety Disorder, Breast Cancer, Depression, Fatigue
- Trial name
- NCT00902330
- Testing
- energy-based therapy
- Volunteers
- 161 people
- Sponsor
- Virginia Commonwealth University
Breast Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Vaccines made from a person's white blood cells may help the body build an effective immune response to kill tumor cells. Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways.
- Trial name
- NCT00266110
- Testing
- sargramostim, therapeutic autologous dendritic cells, trastuzumab
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Cancer
Trastuzumab and Oxaliplatin in Patients With Metastatic Breast Cancer
This is a phase II study of the combination of oxaliplatin and trastuzumab as first or second line therapy in patients with stage IV, metastatic breast cancer
- Trial name
- NCT00297596
- Testing
- Trastuzumab, Oxaliplatin
- Where
- 7 sites in United States
- Volunteers
- 25 people
- Sponsor
- SCRI Development Innovations, LLC
Breast Cancer
Capecitabine Compared With Vinorelbine in Treating Women With Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known if capecitabine is more effective than vinorelbine in treating metastatic breast cancer.
- Trial name
- NCT00049660
- Testing
- capecitabine, vinorelbine tartrate
- Where
- 12 sites in Belgium, France and 3 more
- Volunteers
- 47 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer
Non-interventional Study to Assess the Effectiveness and Safety of Ribociclib in the Adjuvant Therapy of Hormone Receptor Positive (HR+) HER2-negative Stage II and III Breast Cancer in Real Clinical Practice in Russia
This prospective, observational, multicenter study aims at evaluating the efficacy of adjuvant ribociclib in combination with hormone therapy (aromatase inhibitor ± GnRH aginost) in various subgroups of patients with HR+HER2…
- Trial name
- ELEGANCE (NCT06930859)
- Testing
- Ribociclib, Letrozole, Anastrozole
- Where
- 42 sites in Russia
- Volunteers
- 2,766 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer, Brain Metastases
ANG1005 in Breast Cancer Patients With Recurrent Brain Metastases
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in breast cancer patients with recurrent brain metastases.
- Trial name
- NCT02048059
- Testing
- ANG1005
- Where
- 19 sites in United States
- Volunteers
- 72 people
- Sponsor
- Angiochem Inc
Breast Cancer
A Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Primary Breast Cancer
This study will evaluate the effect of Avastin (15mg/kg iv) in combination with Docetaxel and Xeloda, given as pre-operative therapy to patients with primary breast cancer.
- Trial name
- NCT02005549
- Testing
- bevacizumab [Avastin], docetaxel, capecitabine [Xeloda]
- Where
- Austria
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Breast Cancer
Phase II Clinical Study of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
The purpose of this study is to assess the efficacy and safety of Pyrotinib Combined With Etoposide to Treat HER2-positive Advanced Breast Cancer
- Trial name
- NCT03923179
- Testing
- Pyrotinib, Etoposide
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Chinese Academy of Medical Sciences
Breast Cancer
A Study of Subcutaneously Administered Herceptin (Trastuzumab) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Breast Cancer
This open-label, randomized crossover study evaluated the quality of life, efficacy, and safety of subcutaneous Herceptin (trastuzumab) injected either into the thigh or the upper arm of participants with early HER2-positive…
- Trial name
- LISAH (NCT01928615)
- Testing
- Trastuzumab - intravenous solution, Trastuzumab - subcutaneous solution, Chemotherapy
- Where
- 2 sites in Austria
- Volunteers
- 2 people
- Sponsor
- Hoffmann-La Roche